公开(公告)号：US20200276286A1

公开(公告)日：2020-09-03

申请号：US16647245

申请日：2018-09-13

Applicant: Rita E. Serda ,  C. Jeffrey Brinker ,  Jacob Ongudi Agola ,  Jimin Guo ,  Sarah Adams ,  STC.UNM

Inventor： Rita E. Serda ,  C. Jeffrey Brinker ,  Jacob Ongudi Agola ,  Jimin Guo ,  Sarah Adams

IPC: A61K39/00 ,  A61K39/39

Abstract: A silicified cell replica includes a silicified cell or a silicified subcellular fragment. The silicified cell replica may be used to induce an immunological response, treat a bacterial infection, or treat a patient with cancer.

公开(公告)号：US20240115676A1

公开(公告)日：2024-04-11

申请号：US18267878

申请日：2021-12-14

Applicant: Rita E. Serda ,  Jimin Guo ,  UNM Rainforest Innovations

Inventor： JIMIN GUO ,  RITA E. SERDA

IPC: A61K39/00 ,  A61P35/00 ,  A61P37/04

CPC classification number: A61K39/0011 ,  A61P35/00 ,  A61P37/04 ,  A61K2039/5152 ,  A61K2039/55561

Abstract: In one aspect, a method generally includes obtaining a dried silicified cell that has been stored for at least 24 hours without cryopreservation and rehydrating the dried silicified cell in a pharmaceutically acceptable carrier. The method can further include surface modifying the silicified cell with at least one immunogenic molecule. The method can further include administering the rehydrated silicified cell to a subject. In some embodiment, the dried silicified cell has been stored for at least 14 days without cryopreservation. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject a chemotherapeutic agent effective to treat the tumor and administering to the subject a silicified cell vaccine effective to treat the tumor.

公开(公告)号：US20220125835A1

公开(公告)日：2022-04-28

申请号：US17436872

申请日：2020-03-03

Applicant: Rita E. Serda ,  Jimin Guo ,  UNM RAINFOREST INNOVATIONS

Inventor： Rita E. Serda ,  Jimin Guo

IPC: A61K35/13 ,  C12N5/00 ,  C12N5/09

Abstract: A pharmaceutical composition includes a silicified cell or fraction thereof, a cationic layer disposed on at least a portion of the surface of the silicified cell or fraction thereof, and an immunomodulatory moiety bound to at least a portion of the cationic layer. Alternatively, the pharmaceutical composition includes a silicified cell or fraction thereof, a cationic layer disposed on at least a portion of the surface of the silicified cell or fraction thereof, an anionic layer disposed on at least a portion of the cationic layer, and an immunomodulatory moiety bound to at least a portion of the anionic layer.

公开(公告)号：US20230149456A1

公开(公告)日：2023-05-18

申请号：US17916193

申请日：2021-03-30

Applicant: Rita E. Serda ,  Jimin Guo ,  Achraf Noureddine ,  Stefan A. Franco ,  Henning DeMay ,  UNM RAINFOREST INNOVATIONS

Inventor： Rita E. Serda ,  Jimin Guo ,  Achraf Noureddine ,  Stefan A. Franco ,  Henning DeMay

IPC: A61K35/13 ,  B82Y5/00 ,  A61K35/74 ,  A61K35/76

CPC classification number: A61K35/13 ,  B82Y5/00 ,  A61K35/74 ,  A61K35/76

Abstract: A silicified cell includes a nanoparticle that carries a bioactive agent. The silicified call can be a tumor cell, a bacterial cell, a virus, or a silicifiable compartment or fragment thereof. The silicified cell can optionally include an immunomodulatory moiety that may be carried within pores of the nanoparticle and/or bound to the surface of the nanoparticle. The silicified cell can be used as a prophylactic or therapeutic treatment for treating tumors or bacterial infections.